AI assistant
ACRUX LIMITED — Capital/Financing Update 2016
Jan 28, 2016
64293_rns_2016-01-28_83d240e9-ff76-45e9-966e-6a3e6dce0c81.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ACRUX (ACR) - ASX ANNOUNCEMENT
29 JANUARY 2016
AXIRON NET SALES, QUARTER TO 31 DECEMBER 2015
==> picture [483 x 10] intentionally omitted <==
Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US$41.6 million in its financial results for the quarter ending 31 December 2015, up from US$41.4 million for the previous quarter to 30 September, 2015.
Axiron net sales for the calendar year 2015 are shown in the following table:
| Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | Total 2015 |
|---|---|---|---|---|
| US$39.1m | US$32.4m | US$41.4m | US$41.6m | US$154.5m |
Net sales for the second half of 2015 increased 16.1%, when compared to the first half of 2015, and are comparable to the second half of 2014. Axiron held a 2015 exit market share of 14.4%, again comparable to 2014.
For further information, contact
Michael Kotsanis, CEO and Managing Director: 03 8379 0100
About Acrux
Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch[TM] , a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.
For further information on Acrux, visit www.acrux.com.au
==> picture [541 x 82] intentionally omitted <==